MAP Kinase Signaling
| CSTコード |
包装 |
希望納入価格 (円) |
国内在庫  |
ご登録代理店情報  カスタマー情報にご登録いただいた代理店を表示しています。
ご登録代理店の変更は こちら。 |
| #1020S | 100 μg | 16,000 | |
|
JUN抗体製品一覧
| 使用目的 | |
| Phospho-c-Jun (Ser73) Antibody (#9164)の反応をブロックし、抗体の反応特異性を確認するために使用 |
Western Blotting

Western blot analysis of whole cell lysates from NIH/3T3 cells treated and untreated with UV light, probed with Phospho-c-Jun (Ser63) II Antibody #9261 (left) and with the same antibody preincubated with antigen-specific blocking peptide (right).
IHC-P (paraffin)

Immunohistochemical analysis of paraffin-embedded human breast carcinoma, using Phospho-c-Jun (Ser63) (54B3) Rabbit mAb in the presence of control peptide (left) or Phospho-c-Jun (Ser63) II Blocking Peptide (#1020) (right).
c-Jun is a member of the Jun Family containing c-Jun, JunB and JunD, and is a component of the transcription factor AP-1 (activator protein-1). AP-1 is composed of dimers of Fos, Jun and ATF family members and binds to and activates transcription at TRE/AP-1 elements (reviewed in 1). Extracellular signals including growth factors, chemokines and stress activate AP-1-dependent transcription. The transcriptional activity of c-Jun is regulated by phosphorylation at Ser63 and Ser73 through SAPK/JNK (reviewed in 2). Knock-out studies in mice have shown that c-Jun is essential for embryogenesis (3), and subsequent studies have demonstrated roles for c-Jun in various tissues and developmental processes including axon regeneration (4), liver regeneration (5) and T cell development (6). AP-1 regulated genes exert diverse biological functions including cell proliferation, differentiation, and apoptosis, as well as transformation, invasion and metastasis, depending on cell type and context (7-9). Other target genes regulate survival as well as hypoxia and angiogenesis (8,10). c-Jun has emerged as a promising therapeutic target for cancer, vascular remodeling, acute inflammation, as well as rheumatoid arthritis (11,12).
-
Jochum, W. et al. (2001) Oncogene 20, 2401-12.
-
Davis, R.J. (2000) Cell 103, 239-52.
-
Hilberg, F. et al. (1993) Nature 365, 179-81.
-
Raivich, G. et al. (2004) Neuron 43, 57-67.
-
Behrens, A. et al. (2002) EMBO J 21, 1782-90.
-
Riera-Sans, L. and Behrens, A. (2007) J Immunol 178, 5690-700.
-
Leppä, S. and Bohmann, D. (1999) Oncogene 18, 6158-62.
-
Shaulian, E. and Karin, M. (2002) Nat Cell Biol 4, E131-6.
-
Weiss, C. and Bohmann, D. (2004) Cell Cycle 3, 111-3.
-
Karamouzis, M.V. et al. (2007) Mol Cancer Res 5, 109-20.
-
Kim, S. and Iwao, H. (2003) J Pharmacol Sci 91, 177-81.
-
Dass, C.R. and Choong, P.F. (2008) Pharmazie 63, 411-4.